| INTRODUCTION
Obsessive-compulsive disorder (OCD) is characterised by repetitive and intrusive thoughts, urges, images or fears (obsessions), and repetitive behaviours or mental acts (compulsions). Common symptoms include fears of contamination and excessive hand washing, preoccupation with symmetry and ordering, intrusive and distressing unacceptable or taboo thoughts, and repetitive checking. These types of symptoms tend to be similar regardless of cultural background (Matsunaga et al., 2008) . Throughout the world, OCD is thought to occur in 0.8 to 2% of the population (Ruscio, Stein, Chiu, & Kessler, 2010) . It is viewed as a relapsing remitting disorder (Eisen et al., 2013; Skoog & Skoog, 1999) , and patients with OCD often do not receive optimal treatment (Sorsdahl et al., 2013) . Treatment guidelines (Baldwin et al., 2014; Bandelow et al., 2012; Marazziti & Consoli, 2010 ; National Institute for Health and Clinical Excellence, 2005) recommend selective serotonin reuptake inhibitors (SSRIs) or exposure and response prevention (ERP) as first-line treatments. However, response to pharmacological treatment is frequently inadequate (Schruers, Koning, Luermans, Haack, & Griez, 2005) and further limited by poor insight, medication nonadherence, and/or adverse effects.
Cross-cultural studies of OCD have been encouraged (Stein & Rapoport, 1996) , and research assessing international prescribing trends for OCD can inform us whether treatment preferences vary from one country to another. Building on the findings of a previous international survey (Brakoulias et al., 2016) , this study thus had three aims: (a) to compare the frequencies of psychotropic agent use for OCD across a larger number of countries, with a more specific focus on the types of SSRIs and antipsychotics and other pharmacological agents used in each country, (b) to report on the use of novel therapeutic modalities, for example, transcranial magnetic stimulation (TMS), in OCD, and (c) to determine the frequency of use of ERP in OCD and its accessibility. Based on existing literature, study hypotheses were as follows: (a) Use of pharmacological agents for OCD varies significantly between countries (Brakoulias et al., 2016; Van Ameringen et al., 2014) , (b) SSRIs are the most commonly prescribed pharmacotherapeutic agents for OCD (Brakoulias et al., 2013; Brakoulias et al., 2016) , and (c) ERP is used less frequently in countries where access to trained therapists is limited and costly.
| METHODS
The first author V. B. wrote to leading international OCD researchers, asking them to take part in the large international survey. These researchers worked predominantly in publicly funded specialised The severity of OCD was assessed with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS; Goodman et al., 1989) in all samples, whereas diagnosis of OCD was made with the Structured Clinical
Interview for DSM-IV-TR Axis I Disorders (First, Spitzer, Gibbon, & Williams, 2007) , the Mini-International Neuropsychiatric Interview (Sheehan et al., 1998; Sheehan & Lecrubier, 2010) , or the Anxiety Disorders Interview Schedule for DSM-IV Lifetime Version (Brown, Barlow, & Di Nardo, 1994) .
Consistency of summary statistics across countries was assessed using conventional chi-square tests for categorical variables (i.e., gender, referral type, and medication usage) and the Q heterogeneity statistic for continuous variables (i.e., age and Y-BOCS score). Analyses were performed in SAS version 9.4 (SAS Institute).
| RESULTS
Data were collected on 7,340 participants with OCD from 15 coun- for consistency in Y-BOCS distribution across countries was <0.0001).
All participants in the samples from the U.K. and the Boston U.S.
centres were referred by a doctor, whereas the majority of the participants from the sample from India (n = 547; 68.2%) were self-referred (overall p value for consistency in referral patterns across countries was <0.0001).
Just over one half (n = 3910; 53.3%) of the total sample were taking one of the SSRIs (Table 2 ). There was a significant variation in the rates of SSRI use between different countries (Figure 1) , ranging from the lowest in the Chinese sample (n = 98; 28.7%) to the highest in the Argentinian sample (n = 314; 88.0%); Table 2 also shows the frequency with which various SSRIs were used in different countries.
Citalopram and fluoxetine were not available in Japan, but there was access to all six SSRIs in all other countries. Fluoxetine (n = 972;
13.2%) and fluvoxamine (n = 913; 12.4%) were the most commonly used SSRIs, whereas citalopram (n = 398; 5.4%) was the least commonly used. Escitalopram was the most frequently used SSRI in the samples from Germany, Rome, and Spain. Paroxetine was the most frequently used SSRI in the Japanese sample. Sertraline was the most frequently prescribed agent in the Chinese sample. Table 3 shows the frequency of use of other antidepressants and benzodiazepines. Of the SNRIs, only venlafaxine was available in most countries, and it was used in between 2% and 10% of the samples.
The overall clomipramine use was common (n = 703; 11%), but with a large variability, ranging from 0.3% (n = 1) in the Chinese sample to 39.2% (n = 140) in the Argentinian sample. In the total sample, benzodiazepines were commonly used (n = 986; 15.2%), particularly in the Americas, Rome, Japan, and Spain. Table 4 shows that atypical antipsychotics were used in 23.3%
(n = 1,368) of the sample. Use of atypical antipsychotics was highest in Argentina (n = 156; 43.7%) and Japan (n = 154; 43.3%) and lowest in China (n = 16; 4.7%). Risperidone (n = 428; 7.3%) and aripiprazole (n = 415; 7.1%) were the most commonly used antipsychotics internationally. Less than 5% (n = 275) of the total sample were taking typical antipsychotic agents, with rates being highest in the Spanish and Mexican samples.
Data on the use of mood stabilisers, anticonvulsants, and other pharmacological agents are presented in existing research has consistently found that no SSRI is superior to another with regard to treatment outcome for OCD (Skapinakis et al., 2016) . Therefore, factors such as side effects of the specific SSRIs, their half-life, availability, cost, and clinician preference may play a role in the choice of SSRIs for OCD.
Clomipramine still has an important role in the treatment armamentarium for OCD, despite its high rate of adverse effects. It was used in 11% of the entire sample with rates being higher in sites with greater mean OCD severity. For instance, the sample from Argentina had the highest mean Y-BOCS score of all sites and also the highest rate of clomipramine use (39.2%).
Atypical antipsychotics were used commonly (23.3%), which is likely to reflect the resistant nature of OCD patients who may have seen several clinicians before coming to a specialised OCD clinic. This finding is similar to the results of a multisite study (Van Ameringen et al., 2014) , reporting that 30% of patients with OCD received augmentation with atypical antipsychotics. The preference for risperidone and aripiprazole as augmenting agents may relate to their relatively favourable side effect profiles and the greater number of reported trials using these agents (Albert et al., 2016; Veale et al., 2014) . Most of the sites that were surveyed in this study were collecting data for more than a decade, which might have resulted in an overrepresentation of antipsychotic medication that were introduced earlier, for example, risperidone and olanzapine, compared with antipsychotic medication that appeared more recently, such as paliperidone and lurasidone.
Among other pharmacological agents, this study repeated the findings of the previous survey (Brakoulias et al., 2016) 
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Total survey sample (n = 6,082) The use of TMS has also developed since OCD treatment guidelines were last written, and new treatment guidelines will need to reconsider the role of TMS in the treatment of OCD (Lusicic, Schruers, Pallanti, & Castle, 2018; Rehn, Eslick, & Brakoulias, 2018) . Defining the role of newer treatment strategies in guidelines encourages clinicians to consider such treatment approaches.
It was surprising that less than a third (31.5%) of the participants had received ERP in the previous/preceding 6 months, considering that the average Y-BOCS score was in the severe range (24.8) and that the centres were specialised in treating OCD. This relatively low rate of ERP is not in keeping with treatment guidelines and research evidence supporting its use prior to antipsychotic augmentation for OCD (Foa et al., 2007; Simpson et al., 2013) . A possible reason for this is a difficulty accessing ERP, so that ERP is "bypassed" and medication is administered instead. It should also be noted that not all centres collected information relating to psychological therapies (the total sample was only 4,086). The Spanish site is led by psychologists, and this is likely to explain the high rate of ERP at this site. There are also studies indicating that ERP is less cost effective when compared with SSRI therapy (Skapinakis et al., 2016) .
The rates of SSRI use and ERP within the samples indicate that some patients who were referred to these expert centres were not receiving first-line evidence-based treatments for OCD. Thus, there is benefit in providing education on the treatment of OCD to primary care clinicians. It does appear that centres with samples that reported greater severity as measured by the Y-BOCS (see Table 1 ) also reported higher rates of SSRI use (see Table 2 ).
This survey is primarily limited by the heterogeneity within the international sample. Each specialised centre had varying data collection periods, methods of collecting the data, referral criteria, modes of referral, and levels of OCD severity. Some centres did not collect data on certain variables, and this resulted in lower total sample sizes for some variables. It should be emphasised that the low rates of psychotropic use, for example, in China, do not reflect the prescribing practices of the expert centres, but rather the treatments used by participants when presenting to the expert centre for the first time.
Although the tables do not suggest the use of multiple antidepressants or antipsychotic agents, the survey did not specifically ask how often multiple pharmacological agents were used. The samples from which the survey results derived were collected over long periods of time,
with some centres having collected data since 1990 (the years of data collection at each site have been detailed in Table 1 ). As discussed, this limits our interpretation of the survey results in regard to the prevalence of antipsychotic augmentation.
The health care systems in regard to access to services and funding models are different in each of the countries. Any future attempt to assess for treatment preferences of referrers to specialist OCD centres should attempt to restrict the dates of data collection, standardise referral criteria, and standardise methods of data collection. The survey also sparks interest in better understanding which treatment strategies are preferred in clinical practice. Future large naturalistic studies may aid our understanding of the real-life treatment response rates, discontinuation rates, and most relevant adverse effects.
| CONCLUSION
In conclusion, this survey provides readers with more detailed international prescribing characteristics in a larger sample than our previous survey. In particular, it shows that fluoxetine and fluvoxamine were among the most frequently prescribed SSRIs and that risperidone and aripiprazole were the most frequently prescribed antipsychotic agents. Novel biological therapies do not appear to be in common use for OCD, and their use may need to be considered in new treatment guidelines. The study also highlighted the underutilisation of ERP and the difficulty that many patients in different countries have in accessing ERP. The findings emphasise the need for updated and well-circulated treatment guidelines for OCD.
